Mangoceuticals and Nuclea Energy Announce Merger to Power AI Data Centers with Microreactors

Key Facts

In a move reflecting the growing trend toward securing sustainable power for the tech sector, Mangoceuticals has entered into a definitive business combination agreement with Nuclea Energy, a specialist in advanced nuclear technology. The deal aims to bring Nuclea's Morpheus microreactor to public markets to address the surging power demand from AI and data centers. Nuclea is advancing the project through an 18-month roadmap focused on achieving regulatory and commercial readiness.

This agreement comes as technology firms seek reliable energy solutions, with the merger focusing on lead-cooled micro-modular nuclear reactors. According to reports, the transaction is subject to regulatory hurdles, including approvals from Mangoceuticals stockholders and Nasdaq, with economic and voting rights limited by a 19.99% cap of outstanding common stock prior to closing. This strategic pivot is seen as an effort to capitalize on AI infrastructure growth, though it faces the inherent regulatory complexities of the nuclear sector.

Regarding market performance, MGRX shares stood at $0.5527 at the close of July 29, 2026, following a session high of $0.56 and a low of $0.52. In the absence of immediate nuclear-sector catalysts in the upcoming economic calendar, investors will likely focus on the company's 18-month progress toward licensing and any further updates regarding the initial listing application on Nasdaq.